Accelerate Diagnostics (MEX:AXDX) Net Change in Cash: MXN53.5 Mil (TTM As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AXDX Accelerate Diagnostics Inc MEX:AXDX
12 GF Score
Price MXN1.75
View Full Analysis

What is Accelerate Diagnostics Net Change in Cash?

Accelerate Diagnostics MEX:AXDX 12 Net Change in Cash is MXN53.5 Mil as of Dec. 2024. GuruFocus rates MEX:AXDX with a GF Score™ of 12/100.

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Accelerate Diagnostics's Net Change in Cash for the three months ended in Dec. 2024 was MXN-95.8 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was MXN53.5 Mil.

Accelerate Diagnostics Net Change in Cash Historical Data

* Premium members only.

The historical data trend for Accelerate Diagnostics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accelerate Diagnostics Net Change in Cash Chart

Accelerate Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -501.93 84.46 -97.34 -386.45 61.73

Accelerate Diagnostics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -136.20 40.96 -110.25 218.62 -95.79
MEX:AXDX
12GF Score
Accelerate Diagnostics Inc MEX:AXDX
Net Change in Cash is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accelerate Diagnostics Net Change in Cash Calculation

Accelerate Diagnostics's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-504.583+-10.616+564.209+12.722
=61.7

Accelerate Diagnostics's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-105.697+0+-12.221+22.128
=-95.8

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN53.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Change in Cash →
What does a Net Change in Cash of MXN53.5 Mil mean?
Accelerate Diagnostics (MEX:AXDX) has a Net Change in Cash of MXN53.5 Mil as of Dec. 2024. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for Accelerate Diagnostics and its competitors.
Is Accelerate Diagnostics' Net Change in Cash too high?
Accelerate Diagnostics' current Net Change in Cash is MXN53.5 Mil. Overall, Accelerate Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Accelerate Diagnostics' Net Change in Cash compare to MSIU and BIOLQ?
Accelerate Diagnostics' Net Change in Cash of MXN53.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Change in Cash for a Medical Devices & Instruments company?
A good Net Change in Cash depends on the Medical Devices & Instruments industry context. However, Net Change in Cash should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Change in Cash mean?
A high Net Change in Cash can signal that a stock is expensive relative to its fundamentals. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for Accelerate Diagnostics and its competitors. Accelerate Diagnostics's current Net Change in Cash is MXN53.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accelerate Diagnostics stock overvalued right now?
Accelerate Diagnostics (MEX:AXDX) has a current Net Change in Cash of MXN53.5 Mil. The current Net Change in Cash is MXN53.5 Mil. Accelerate Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Change in Cash calculated?
Net Change in Cash is calculated from a company's financial statements. For Accelerate Diagnostics (MEX:AXDX), the current Net Change in Cash is MXN53.5 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accelerate Diagnostics Business Description

Address 3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.
12GF Score

Get the complete analysis for MEX:AXDX

Net Change in Cash is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1.75
Price